Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1080-1087

  Waring, Jeffrey F ^a   Liguori, Michael J ^a   Luyendyk, James P ^b   Maddox, Jane F ^b   Ganey, Patricia E ^b   Stachlewitz, Robert F ^a   North, Colin ^b   Blomme, Eric A G ^a   Roth, Robert A ^b  

^a ABBOTT LABORATORIES   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; LEUKOCYTE ACTIVATION; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALE; MICROARRAY ANALYSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALANINE TRANSAMINASE; ANIMALS; CHEMOKINES; CHEMOKINES, CXC; DRUG SYNERGISM; FLUOROQUINOLONES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; NAPHTHYRIDINES; NEUTROPHILS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33644781852     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.096347     Document Type: Article

References (36)

1. Anderson VE and Osheroff N (2001) Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7:337-353.
2. Ball P, Mandell L, Niki Y, and Tillotson G (1999) Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 21:407-421.
3. Bertino J and Fish D (2000) The safety profile of the fluoroquinolones. Clin Ther 22:798-817.
4. Brown AP, Schultze AE, Holdan WL, Buchweitz JP, Roth RA, and Ganey PE (1996) Lipopolysaccharide-induced hepatic injury is enhanced by polychlorinated biphenyls. Environ Health Perspect 104:634-640.
5. Buchweitz JP, Ganey PE, Bursian SJ, and Roth RA (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460-467.
6. Bundschuh DS, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, and Wendel A (1997) Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide- desensitized mice. J Immunol 158:2862-2871.
7. Burczynski ME, McMillian M, Cirvo J, Li L, Parker JB, Dunn RT, Hicken S, Farr S, and Johnson MD (2000) Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 58:399-415.
8. Calkins CM, Bensard DD, Shames BD, Pulido EJ, Abraham E, Fernandez N, Meng X, Dinarello CA, and McIntyre RC Jr (2002) IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. J Endotoxin Res 8:59-67.
9. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, and Lamy M (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-362.
10. Gujral JS, Hinson JA, Farhood A, and Jaeschke H (2004) NADPH oxidase-derived oxidant stress is critical for neutrophil cytotoxicity during endotoxemia. Am J Physiol 287:G243-G252.
11. Hewett JA, Jean PA, Kunkel SL, and Roth RA (1993) Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 265:G1011-G1015.
12. Jaeschke H, Farhood A, and Smith CW (1990) Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 4:3355-3359.
13. Jaeschke H, Farhood A, and Smith CW (1991) Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism. Am J Physiol 261:G1051-G1056.
14. Kelly NM and Cross AS (1992) Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice. FEMS Microbiol Immunol 4:317-322.
15. Knowles SR, Uetrecht J, and Shear NH (2000) Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 356:1587-1591.
16. Lemaire I, Yang H, Lafont V, Dornand J, Commes T, and Cantin MF (1996) Differential effects of macrophage- and granulocyte-macrophage colony-stimulating factors on cytokine gene expression during rat alveolar macrophage differentiation into multinucleated giant cells (MGC): role for IL-6 in type 2 MGC formation. J Immunol 157:5118-5125.
17. Liguori MJ, Anderson LM, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, and Waring JF (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41:177-186.
18. Lubasch A, Keller I, Borner K, Koeppe P, and Lode H (2000) Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 44:2600-2603.
19. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, and Roth RA (2003) Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 307:9-16.
20. Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, and Roth RA (2005) Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 314:1023-1031.
21. Molnar RG, Wang P, Ayala A, Ganey PE, Roth RA, and Chaudry IH (1997) The role of neutrophils in producing hepatocellular dysfunction during the hyperdynamic stage of sepsis in rats. J Surg Res 73:117-122.
22. Park BK, Kitteringham NR, Powell H, and Pirmohamed M (2000) Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 153:39-60.
23. Rajagopalan D (2003) A comparison of statistical methods for analysis of high density oligonucleotide array data. Bioinformatics 19:1469-1476.
24. Ramrakhiani S, Brunt EM, and Bacon BR (1998) Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 93:822-826.
25. Roth RA, Luyendyk JP, Maddox JF, and Ganey PE (2003) Inflammation and drug idiosyncrasy-is there a connection? J Pharmacol Exp Ther 307:1-8.
26. Shenton JM, Chen J, and Uetrecht JP (2004) Animal models of idiosyncratic drug reactions. Chem Biol Interact 150:53-70.
27. Shinohara H, Yano S, Bucana CD, and Fidler IJ (2000) Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells. J Immunol 164:2728-2737.
28. Sissi C and Palumbo M(2003) The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anticancer Agents 3:439-450.
29. Snipes MB, Barnett AL, Harkema JR, Hotchkiss JA, Rebar AH, and Reddick LJ (1995) Specific biological effects of an anti-rat PMN antiserum intraperitoneally infected into f344/n rats. Vet Clin Pathol 24:11-17.
30. Suzuki K, Hino M, Hato F, Tatsumi N, and Kitagawa S (1999) Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood 93:341-349.
31. Takafuji S, Ishida A, Miyakuni Y, and Nakagawa T (2003) Matrix metalloproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol 13:50-55.
32. Tiegs G, Barsig J, Matiba B, Uhlig S, and Wendel A (1994) Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J Clin Investig 93:2616-2622.
33. Waring JF and Anderson MG (2005) Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Dev 8:59-65.
34. Waring JF and Halbert DN (2002) The promise of toxicogenomics. Curr Opin Mol Ther 4:229-235.
35. Yang Y, Blomme EA, and Waring JF (2004) Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 150:71-85.
36. Yee SB, Hanumegowda UM, Hotchkiss JA, Ganey PE, and Roth RA (2003) Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci 72:43-56.